On July 16, 2012, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired HIV infection in adults at high risk.
- Questions and Answers on Truvada
Truvada for PrEP Fact Sheet: Ensuring Safe and Proper Use(PDF - 375KB) FDA approves first drug for reducing the risk of sexually acquired HIV infection[ARCHIVED]
FDA news release (7/16/2012)
FDA Approves First Medication to Reduce HIV Risk
FDA Consumer Update article